Gyre Therapeutics Past Earnings Performance
Past criteria checks 0/6
Gyre Therapeutics's earnings have been declining at an average annual rate of -84631.9%, while the Biotechs industry saw earnings growing at 15% annually. Revenues have been growing at an average rate of 10.7% per year.
Key information
-84,631.9%
Earnings growth rate
-76,085.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 10.7% |
| Return on equity | -89.9% |
| Net Margin | -75.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Gyre Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 116 | -88 | 77 | 13 |
| 31 Dec 23 | 113 | -93 | 76 | 14 |
| 30 Sep 23 | 112 | -44 | 77 | 15 |
| 30 Jun 23 | 111 | 5 | 78 | 16 |
| 31 Mar 23 | 104 | 0 | 73 | 17 |
| 31 Dec 22 | 102 | 2 | 72 | 17 |
Quality Earnings: GYRE is currently unprofitable.
Growing Profit Margin: GYRE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if GYRE's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare GYRE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GYRE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: GYRE has a negative Return on Equity (-89.85%), as it is currently unprofitable.